New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
09:04 EDTGALTGalectin Therapeutics announces preclinical data on anti-galectin therapy
Galectin Therapeutics announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease. Treatment of diabetic mice with GR-MD-02 was found to reverse the primary kidney disease associated with diabetes, called diabetic nephropathy, the leading cause of kidney failure, dialysis and kidney transplant. GR-MD-02 is the Company's lead galectin inhibitor in development for the treatment of liver fibrosis, including non-alcoholic steatohepatitis, or NASH, liver disease. In the preclinical study, diabetic mice developed histological findings consistent with diabetic nephropathy, consisting of glomerular lesions in the form of diffuse mesangial matrix accumulation and proliferation. The kidneys of the diabetic mice also showed fibrosis evidenced by interstitial collagen deposition. Treatment with GR-MD-02 reduced the mesangial matrix accumulation, which suggests the drug suppressed the production and/or accumulation of extracellular matrix components. Additionally, GR-MD-02 markedly reduced the area of interstitial fibrosis. These results demonstrate the anti-fibrotic efficacy of GR-MD-02 in the kidney and its therapeutic potential in diabetic nephropathy as well as other chronic kidney diseases.
News For GALT From The Last 14 Days
Check below for free stories on GALT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
11:14 EDTGALTHigh option volume stocks
09:24 EDTGALTGalectin Therapeutics comments on reactions to GR-MD-02 phase 1 results
Galectin Therapeutics commented on market and social media reactions to the announced results of cohort 2 of its phase 1 clinical trial in patients with NASH with advanced fibrosis. The company stated, "While the results of the clinical trial were positive, the market reacted negatively to this report. We believe the reaction was fueled in part by certain commentary on social media sites and the Internet and we strongly disagree with these interpretations of our data". "There is a large amount of scientific literature showing galectin-3 is a critical protein in fibrosis". "Certain commentators on social media labeled the second cohort results, 'a flop.' This is simply not accurate. The primary endpoints for the phase 1 trial have always been safety and pharmacokinetics and have been successfully met for each cohort completed." "While the phase 1 trial is still ongoing, we deem the phase 1 clinical trial a success up to this point." "Exploratory biomarkers were included to aid in the design of a phase 2 program that will be focused on showing efficacy, and for this they are serving their purpose." "We are not dependent on biomarker data for a phase 2 clinical trial". "The development program for GR-MD-02 for NASH with advanced fibrosis remains on track". "Upon completion of the third cohort, which has already infused two patients, we will initiate a phase 2 clinical trial program to definitively evaluate the therapeutic potential of this promising therapy using a standard endpoint of liver biopsy to assess efficacy".
July 29, 2014
12:13 EDTGALTOn The Fly: Midday Wrap
Subscribe for More Information
11:37 EDTGALTHigh option volume stocks
Subscribe for More Information
10:39 EDTGALTGalectin drug showed no difference from placebo, The Street reports
Subscribe for More Information
08:42 EDTGALTGalectin Therapeutics drops after posting Phase I GT-020 slides
Subscribe for More Information
July 28, 2014
12:59 EDTGALTGalectin Therapeutics volatility up into Cohort 2 Phase 1 clinical trial results
Subscribe for More Information
12:44 EDTGALTGalectin pays for misleading press releases, The Street's Feuerstein says
Subscribe for More Information
11:00 EDTGALTHigh option volume stocks:
Subscribe for More Information
July 25, 2014
08:55 EDTGALTGalectin Therapeutics to host conference call
Conference call to discuss the Cohort 2 Phase 1 clinical trial results will be held on July 29 at 8:30 am. Webcast Link
July 22, 2014
10:46 EDTGALTHigh option volume stocks: SBAC KS EDU PII GALT EJ AXL TSEM HLF BCOR
Subscribe for More Information
08:44 EDTGALTGalectin Therapeutics announces first patient dosed in GR-MD-02 Phase 1B trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use